1. PCSK9 Activity Is Potentiated Through HDL Binding
- Author
-
Burnap, Sean A, Sattler, Katherine, Pechlaner, Raimund, Duregotti, Elisa, Lu, Ruifang, Theofilatos, Konstantinos, Takov, Kaloyan, Heusch, Gerd, Tsimikas, Sotirios, Fernández-Hernando, Carlos, Berry, Sarah E, Hall, Wendy L, Notdurfter, Marlene, Rungger, Gregorio, Paulweber, Bernhard, Willeit, Johann, Kiechl, Stefan, Levkau, Bodo, and Mayr, Manuel
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Sciences ,Atherosclerosis ,Cardiovascular ,Clinical Research ,Heart Disease ,Heart Disease - Coronary Heart Disease ,Apolipoprotein C-III ,Biomarkers ,Coronary Artery Disease ,Female ,Hep G2 Cells ,Humans ,Lipoproteins ,HDL ,Male ,Middle Aged ,Postprandial Period ,Proprotein Convertase 9 ,Protein Binding ,Proteome ,apolipoproteins ,coronary artery disease ,cardiovascular diseases ,lipoproteins ,mass spectrometry ,Cardiorespiratory Medicine and Haematology ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
RationaleProprotein convertase subtilisin/kexin type 9 (PCSK9) circulates in a free and lipoprotein-bound form, yet the functional consequence of the association between PCSK9 and high-density lipoprotein (HDL) remains unexplored.ObjectiveThis study sought to interrogate the novel relationship between PCSK9 and HDL in humans.Methods and resultsComparing lipoprotein and apolipoprotein profiles by nuclear magnetic resonance and targeted mass spectrometry measurements with PCSK9 levels in the community-based Bruneck (n=656) study revealed a positive association of plasma PCSK9 with small HDL, alongside a highly significant positive correlation between plasma levels of PCSK9 and apolipoprotein-C3, an inhibitor of lipoprotein lipase. The latter association was replicated in an independent cohort, the SAPHIR study (n=270). Thus, PCSK9-HDL association was determined during the postprandial response in two dietary studies (n=20 participants each, 8 times points). Peak triglyceride levels coincided with an attenuation of the PCSK9-HDL association, a loss of apolipoprotein-C3 from HDL and lower levels of small HDL as measured by nuclear magnetic resonance. Crosslinking mass spectrometry (XLMS) upon isolated HDL identified PCSK9 as a potential HDL-binding partner. PCSK9 association with HDL was confirmed through size-exclusion chromatography and immuno-isolation. Quantitative proteomics upon HDL isolated from patients with coronary artery disease (n=172) returned PCSK9 as a core member of the HDL proteome. Combined interrogation of the HDL proteome and lipidome revealed a distinct cluster of PCSK9, phospholipid transfer protein, clusterin and apolipoprotein-E within the HDL proteome, that was altered by sex and positively correlated with sphingomyelin content. Mechanistically, HDL facilitated PCSK9-mediated low-density lipoprotein receptor degradation and reduced low-density lipoprotein uptake through the modulation of PCSK9 internalisation and multimerisation.ConclusionsThis study reports HDL as a binder of PCSK9 and regulator of its function. The combination of -omic technologies revealed postprandial lipaemia as a driver of PCSK9 and apolipoprotein-C3 release from HDL.
- Published
- 2021